Whether you’re newly diagnosed, in treatment, or supporting a loved one, our Facebook community is here to share experiences, trusted resources, and hope.
Enter the GroupAround 2–5 % of colorectal cancers overexpress the HER2 protein. HER2 testing (IHC, FISH, or NGS) helps identify patients who may benefit from targeted therapy.
In 2023 the FDA approved tucatinib + trastuzumab, while trastuzumab deruxtecan gained a tumor‑agnostic approval in 2024, offering new options after chemotherapy.
Connecting with peers can reduce anxiety, improve coping, and provide real‑world tips for navigating treatment and side effects.